Azeria Therapeutics is the world’s first pioneer factor drug discovery company developing breakthrough treatments for hormone resistant breast cancer patients where there are significant areas of unmet clinical need.

Founded in 2017 by the leading expert in pioneer factors in cancer, Dr Jason Carroll, Azeria is using its  developing a pipeline of small molecules designed to selectively inhibit pioneer factors.

Azeria is initially targeting the essential pioneer factor FOXA1, which has shown to be pivotal in the tumour development and maintenance of oestrogen receptor (ER) positive luminal breast cancer.

Based in Cambridge UK, Azeria successfully raised £5.5 million in a Series A financing, provided by specialist oncology investment fund, the CRT Pioneer Fund, managed by Sixth Element Capital LLP.


Company Details


Steve Myatt


Jason Carroll

Syncona Representatives:

Martin Murphy
Magda Jonikas
Michael Kyriakides

Latest updates

There are currently no updates for Azeria Therapeutics.